NCT07248176
Universal CAR-T Cell Therapy for MM
Recruiting · Not Applicable · Bioray Laboratories · registry updated 2025-12-01
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Inclusion
- Expected survival of at least 3 months;
- Subjects should have measurable disease that meets the IMWG 2016 criteria;
- Previously received at least two lines of prior anti-myeloma therapy ；
- Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
- BCMA positive；
- ECOG score 0-1；
Exclusion
- Pregnant or breastfeeding women;
- History of other malignant tumors;
- Active autoimmune diseases requiring immunotherapy;
- Previously received allogeneic stem cell transplantation;
- Previous use of CAR-T cells or other genetically modified T cell therapies;
- Previously received targeted BCMA therapy;